Nephrology research - The past, present and future

Nature Reviews Nephrology

Volumn 11, Issue 11, 2015, Pages 677-687

  Floege, Jürgen ^a   Mak, Robert H ^b   Molitoris, Bruce A ^c   Remuzzi, Giuseppe ^d   Ronco, Pierre ^e  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Urgences Néphrologiques et Transplantation Rénale Hôpital Tenon 4   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; GENE MUTATION; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MESENCHYMAL STEM CELL; NEPHROLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PODOCYTE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; STEM CELL TRANSPLANTATION; FORECASTING; KIDNEY DISEASES; MEDICAL RESEARCH; TRENDS;

BIOMEDICAL RESEARCH; FORECASTING; HUMANS; KIDNEY DISEASES; NEPHROLOGY;

EID: 84945479338     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.152     Document Type: Review

References (66)

1. Beck. L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11-21 (2009).
2. Clement, L. C. et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17, 117-122 (2011).
3. Hu, M. C. et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J. Am. Soc. Nephrol. 26, 1290-1302 (2015).
4. Machnik, A. et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15, 545-552 (2009).
5. Maass, P. G. et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat. Genet. 47, 647-653 (2015).
6. Antignac, C. et al. The future of polycystic kidney disease research-as seen by the 12 Kaplan awardees. J. Am. Soc. Nephrol. 9, 2081-2095 (2015).
7. Freedman, B. I. et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 87, 176-181 (2015).
8. Fresquet, M. et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J. Am. Soc. Nephrol. 26, 302-313 (2015).
9. Kurts, C., Panzer, U., Anders, H. J. & Rees, A. J. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738-753 (2013).
10. Hato, T. et al. The macrophage mediates the renoprotective effects of endotoxin preconditioning. J. Am. Soc. Nephrol. 26, 1347-1362 (2015).
11. Hall, A. M. & Molitoris, B. A. Dynamic multiphoton microscopy: focusing light on acute kidney injury. Physiology (Bethesda) 29, 334-342 (2014).
12. Lifton, R. P., Gharavi, A. G.& Geller, D. S. Molecular mechanisms of human hypertension. Cell 104, 545-556 (2001).
13. Shibata, S. et al. Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation. Proc. Natl Acad. Sci. USA 111, 15556-15561 (2014).
14. Kestilä, M. et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol. Cell 1, 575-582 (1998).
15. Boute, N. et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat. Genet. 24, 349-354 (2000).
16. Devuyst, O. et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 383, 1844-1859 (2014).
17. Sadowski, C. E. et al. A single-gene cause in 29.5% of cases of steroid resistant nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1279-1289 (2015).
18. Santín, S. et al. Clinical value of NPHS2 analysis in early-and adult-onset steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 6, 344-354 (2011).
19. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 329, 841-845 (2010).
20. Evolve Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482-2494 (2012).
21. Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
22. Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169-2181 (2013).
23. Wuhl, E. et al. Strict blood pressure control and progression of renal failure in children. N. Engl. J. Med. 361, 1639-1650 (2009).
24. Schrier, R. W. et al. Blood pressure in early autosomal dominant kidney disease. N. Engl. J. Med. 371, 2255-2266 (2014).
25. Appel, L. J. et al. Intensive blood pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 363, 918-929 (2010).
26. Parsa, A. et al. APOL1 risk variants, race and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183-2196 (2013).
27. He, J. C., Chuang, P. Y., Ma'ayan, A. & Iyengar, R. Systems biology of kidney diseases. Kidney Int. 81, 22-39 (2012).
28. Loupy, A. et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J. Am. Soc. Nephrol. 25, 2267-2277 (2014).
29. Warnock, D. G. & Mauer, M. Fabry disease: dose matters. J. Am. Soc. Nephrol. 25, 653-655 (2014).
30. Kavanagh, D., Goodship, T. H. & Richards, A. Atypical hemolytic uremic syndrome. Semin. Nephrol. 33, 508-530 (2013).
31. Chang, M. Y. & Ong, A. C. New treatments for autosomal dominant polycystic kidney disease. Br. J. Clin. Pharmacol. 76, 524-535 (2013).
32. Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053-2060 (2002).
33. Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277-2287 (2014).
34. Ronco, P. & Debiec, H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 385, 1983-1992 (2015).
35. Nürnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542-544 (2009).
36. Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544-546 (2009).
37. Loirat, C. et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-015-3076-8.
38. Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407-2418 (2012).
39. Coresh, J. et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311, 2518-2531 (2014).
40. LaRivere, W. B., Irazabal, M. V. & Torres, V. E. Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Translat. Res. 4, 488-498 (2015).
41. Dickson, L. E., Wagner, M. C., Sandoval, R. M. & Molitoris, B. A. The proximal tubule and albuminuria: really! J. Am. Soc. Nephrol. 25, 443-453 (2014).
42. Wagner, M. C. et al. Proximal tubules have the capacity to regulate uptake of albumin. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014111107.
43. Prowle, J. R. et al. Serum creatinine changes associated with critical illness and detection of persistent renal dysfunction after AKI. Clin. J. Am. Soc. Nephrol. 9, 1015-1023 (2014).
44. Gaspari, F. et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 84, 164-173 (2013).
45. GBD Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117-171 (2015).
46. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213-1224 (2008).
47. Luyckx, V. A. & Brenner, B. M. Birth weight, malnutrition and kidney-associated outcomes-a global concern. Nat. Rev. Nephrol. 11, 135-149 (2015).
48. De Vriese, A. S. & Fervenza, F. C. Con: biomarkers in glomerular diseases: putting the cart before the wheel? Nephrol. Dial. Transplant. 30, 885-890 (2015).
49. Ronco, P. Moderator's view: biomarkers in glomerular diseases-translated into patient care or lost in translation? Nephrol. Dial. Transplant. 30, 899-902 (2015).
50. Murray, P. T. et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 85, 513-521 (2014).
51. Ronco, P. & Floege, J. Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? Semin. Immunopathol. 36, 377-379 (2014).
52. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005).
53. Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
54. Grantham, J. J. et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122-2130 (2006).
55. Warady, B. A. et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) cohort. Am. J. Kidney Dis. 65, 878-888 (2015).
56. English, K. & Wood, K. J. Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb. Perspect. Med. 3, a015560 (2013).
57. Mariani, L. H. & Kretzler, M. Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism-individual patient variability in disease presentation, course and response to therapy. Nephrol. Dial. Transplant. 30, 892-898 (2015).
58. Okpechi, I. G., Swanepoel, C. R. & Venter, F. Access to medications and conducting clinical trials in LMICs. Nat. Rev. Nephrol. 11, 189-194 (2015).
59. Armignacco, P. et al. Wearable devices for blood purification: principles, miniaturization, and technical challenges. Semin. Dial. 28, 125-130 (2015).
60. Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 125096 (2014).
61. Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015).
62. Molitoris, B. A. ASN Presidential Address 2013: innovation and individualization-the path forward for nephrology. J. Am. Soc. Nephrol. 25, 893-897 (2014).
63. Horton, R. & Berman, P. Eliminating acute kidney injury by 2015: an achievable goal. Lancet 385, 2551-2552 (2015).
64. Menche, J. et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 347, 1257601 (2015).
65. Kawai, T., Sachs, D. H., Sykes, M. & Cosimi, A. B. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 368, 1850-1852 (2013).
66. Humphreys, B. D. Kidney injury, stem cells and regeneration. Curr. Opin. Nephrol. Hypertens. 23, 25-31 (2014).